Gene · 133396
Papers2,998
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 2,998
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Off-Label Uses of Nemolizumab: A Narrative Review. | J Drugs Dermatol | 2026 | 42826149 | PubTator, text mining | PubMed |
| Rapid Improvement of Refractory Pruritus in Extragenital and Perianal Lichen Sclerosus With Nemolizumab: A Case Report. | Cureus | 2026 | 42799185 | PubTator, text mining | PubMed |
| SPOP-mediated ZMYND8 ubiquitination and phase separation exclusion drives mTOR inhibitor resistance in kidney cancer. | Nat Commun | 2026 | 42778578 | PubTator, text mining | PubMed |
| Decoding MOF-Enzyme-Substrate Compatibility for Universal Biocatalyst Immobilization. | ACS Appl Mater Interfaces | 2026 | 42742227 | PubTator, text mining | PubMed |
| : Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab. | J Drugs Dermatol | 2026 | 42696343 | PubTator, text mining | PubMed |
| Tape Strip Transcriptomics Reveal Nemolizumab Effects on Pruritus, Hyperplasia, Inflammation, and Extracellular Matrix Markers in Patients With Moderate-to-Severe Atopic Dermatitis. | Allergy | 2026 | 42693785 | PubTator, text mining | PubMed |
| Autosomal recessive OSMRβ deficiency: Connecting OSM and/or IL-31 with atopy. | J Hum Immun | 2026 | 42639505 | PubTator, text mining | PubMed |
| Cryo-EM structure of the interleukin-31 receptor complex defines non-canonical interactions that confer receptor specificity. | J Biol Chem | 2026 | 42637078 | PubTator, text mining | PubMed |
| Impact of IL31RA Genetic Variants and Expression on Metastatic Progression in Oral Cavity Squamous Cell Carcinoma. | Oncol Res | 2026 | 42630481 | PubTator, text mining | PubMed |
| Beyond Histamine: Mast Cell-Neuron Communication in Chronic Pruritic and Pain Disorders. | Exp Dermatol | 2026 | 42619475 | PubTator, text mining | PubMed |
| Neddylation-dependent RAB40-Cullin5 E3 ligase complex controls ubiquitin-mediated proteasomal degradation of DNAJC13. | BBA Adv | 2026 | 42602476 | PubTator, text mining | PubMed |
| Structure-Based Discovery of JN210 as a Potent Dual DCN1/HDAC Inhibitor for the Treatment of Nonsmall Cell Lung Cancer. | J Med Chem | 2026 | 42593931 | PubTator, text mining | PubMed |
| Discovery of spirocyclic amide scaffolds as novel neddylation E1 inhibitors to suppress the growth and survival of lung cancer cells. | RSC Med Chem | 2026 | 42559520 | PubTator, text mining | PubMed |
| Construction and mechanism of histone deacetylation related gene prognosis model in esophageal carcinoma. | Sci Rep | 2026 | 42471418 | PubTator, text mining | PubMed |
| Large-scale quaternary structural transitions underlie gain of function of SPOP cancer mutations. | Mol Cell | 2026 | 42442353 | PubTator, text mining | PubMed |
| Induction of human pruriceptors from pluripotent stem cells via transcription factors. | Stem Cell Reports | 2026 | 42425092 | PubTator, text mining | PubMed |
| Correction: mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3IBTK-mediated ubiquitination of eIF4A1 in cancer cells. | Elife | 2026 | 42307616 | PubTator, text mining | PubMed |
| Prurigo nodularis en plaque resolved after a loading dose of nemolizumab. | Proc (Bayl Univ Med Cent) | 2026 | 42269052 | PubTator, text mining | PubMed |
| Targeting IL-31RA with nemolizumab in prurigo nodularis: a systematic review, GRADE-assessed meta-analysis, and trial sequential analysis of randomized controlled trials. | Ann Med Surg (Lond) | 2026 | 42254180 | PubTator, text mining | PubMed |
| Site-specific combinatorial ubiquitination drives the targeted degradation of plasma membrane proteins. | bioRxiv | 2026 | 42244696 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/133396/papers